FP
VRTX icon

FDO Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

FDO Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-23,783
Closed -$3.06M – 313
2017
Q2 		$3.06M Buy
23,783
+251
+1% +$30.2K 0.66% 51
2017
Q1 		$2.57M Sell
23,532
-17,190
-42% -$1.51M 0.64% 59
2016
Q4 		$3M Buy
40,722
+21,450
+111% +$1.75M 1.21% 1
2016
Q3 		$1.68M Sell
19,272
-129
-0.7% -$12.2K 0.73% 46
2016
Q2 		$1.67M Buy
19,401
+12,088
+165% +$1.04M 0.9% 29
2016
Q1 		$581K Buy
+7,313
New +$661K 0.38% 95

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

FDO Partners's VRTX Position: Q3 2017 in Review

FDO Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2017, closing a stake of 23,783 shares — an estimated $3.06M sold.

FDO Partners first reported a position in VRTX in Q1 2016 and held it in 6 quarters. The position peaked at $3.06M in Q2 2017. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

  • FDO Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • FDO Partners sold 23,783 Vertex Pharmaceuticals shares in Q3 2017, an estimated $3.06M.
  • FDO Partners first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • FDO Partners's Vertex Pharmaceuticals position peaked at $3.06M in Q2 2017.
  • 611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on FDO Partners's 13F filing for Q3 2017, filed 13 Nov 2017.